These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31714191)

  • 21. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
    Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
    J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: detection and monitoring at 3T.
    Ittrich H; Lange C; Tögel F; Zander AR; Dahnke H; Westenfelder C; Adam G; Nolte-Ernsting C
    J Magn Reson Imaging; 2007 Jun; 25(6):1179-91. PubMed ID: 17520738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Feasibility of Magnetic Resonance Imaging for Quantification of Liver, Pancreas, Spleen, Vertebral Bone Marrow, and Renal Cortex R2* and Proton Density Fat Fraction in Transfusion-Related Iron Overload.
    İdilman İS; Gümrük F; Haliloğlu M; Karçaaltıncaba M
    Turk J Haematol; 2016 Mar; 33(1):21-7. PubMed ID: 26376710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results.
    de Bazelaire CM; Duhamel GD; Rofsky NM; Alsop DC
    Radiology; 2004 Mar; 230(3):652-9. PubMed ID: 14990831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of liver-specific r2 * of a highly monodisperse USPIO by (59) Fe iron core-labeling in mice at 3 T MRI.
    Raabe N; Forberich E; Freund B; Bruns OT; Heine M; Kaul MG; Tromsdorf U; Herich L; Nielsen P; Reimer R; Hohenberg H; Weller H; Schumacher U; Adam G; Ittrich H
    Contrast Media Mol Imaging; 2015; 10(2):153-62. PubMed ID: 25078884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver iron overload assessment by MRI R2* relaxometry in highly transfused pediatric patients: an agreement and reproducibility study.
    Verlhac S; Morel M; Bernaudin F; Béchet S; Jung C; Vasile M
    Diagn Interv Imaging; 2015 Mar; 96(3):259-64. PubMed ID: 25533496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
    Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent.
    Briley-Saebø K; Hustvedt SO; Haldorsen A; Bjørnerud A
    J Magn Reson Imaging; 2004 Oct; 20(4):622-31. PubMed ID: 15390223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
    Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE
    Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
    Ning P; Zucker EJ; Wong P; Vasanawala SS
    Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Activity Measurements of Brown Adipose Tissue at 7 T Magnetic Resonance Imaging After Application of Triglyceride-Rich Lipoprotein 59Fe-Superparamagnetic Iron Oxide Nanoparticle: Intravenous Versus Intraperitoneal Approach.
    Jung CS; Heine M; Freund B; Reimer R; Koziolek EJ; Kaul MG; Kording F; Schumacher U; Weller H; Nielsen P; Adam G; Heeren J; Ittrich H
    Invest Radiol; 2016 Mar; 51(3):194-202. PubMed ID: 26674208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI with ferumoxytol: A single center experience of safety across the age spectrum.
    Nguyen KL; Yoshida T; Han F; Ayad I; Reemtsen BL; Salusky IB; Satou GM; Hu P; Finn JP
    J Magn Reson Imaging; 2017 Mar; 45(3):804-812. PubMed ID: 27480885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.
    Muehe AM; Feng D; von Eyben R; Luna-Fineman S; Link MP; Muthig T; Huddleston AE; Neuwelt EA; Daldrup-Link HE
    Invest Radiol; 2016 Apr; 51(4):221-227. PubMed ID: 26656202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects.
    Pai AB; Nielsen JC; Kausz A; Miller P; Owen JS
    Clin Pharmacol Ther; 2010 Aug; 88(2):237-42. PubMed ID: 20592725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.
    Toth GB; Varallyay CG; Horvath A; Bashir MR; Choyke PL; Daldrup-Link HE; Dosa E; Finn JP; Gahramanov S; Harisinghani M; Macdougall I; Neuwelt A; Vasanawala SS; Ambady P; Barajas R; Cetas JS; Ciporen J; DeLoughery TJ; Doolittle ND; Fu R; Grinstead J; Guimaraes AR; Hamilton BE; Li X; McConnell HL; Muldoon LL; Nesbit G; Netto JP; Petterson D; Rooney WD; Schwartz D; Szidonya L; Neuwelt EA
    Kidney Int; 2017 Jul; 92(1):47-66. PubMed ID: 28434822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol.
    Christen T; Ni W; Qiu D; Schmiedeskamp H; Bammer R; Moseley M; Zaharchuk G
    Magn Reson Med; 2013 Sep; 70(3):705-10. PubMed ID: 23001902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation.
    Smits LP; Tiessens F; Zheng KH; Stroes ES; Nederveen AJ; Coolen BF
    Atherosclerosis; 2017 Aug; 263():211-218. PubMed ID: 28662398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
    Schwenk MH
    Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.